Cipralex licensed for use in GAD

Lundbeck has received a licence extension for its antidepressant Cipralex (escitalopram) allowing it to be used in the treatment of generalised anxiety disorder (GAD).

Escitalopram is a selective serotonin reuptake inhibitor (SSRI) (also known as 5HT reuptake inhibitors).

Placebo controlled studies have shown that escitalopram given in doses of 10 mg and 20 mg once daily produces almost a 50% response rate in patients with GAD. The beneficial effect is seen from the first week of treatment and is maintained for at least 76 weeks.

The usual initial dose of Cipralex for the treatment of patients over the age of 18 years is 10 mg once daily, increasing to a maximum of 20 mg once daily depending on the patient's response.

Long term treatment of responders may be continued to prevent relapse provided treatment benefits and dose are re-evaluated at regular intervals.

Further information: Lundbeck Ltd, Lundbeck House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LF. Tel: 01908 649966.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...